Stay updated on BMS-986226 Immunotherapy Combo Clinical Trial

Sign up to get notified when there's something new on the BMS-986226 Immunotherapy Combo Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BMS-986226 Immunotherapy Combo Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:25:55.000Z thumbnail image
  5. Check
    4 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to BMS-986226 administered alone or in combination with nivolumab or ipilimumab for patients with advanced solid tumors.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:55.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed information about eligibility criteria for clinical trial participants, including examples and a link for more information. Previously, this section had no information provided.
    Difference
    20%
    Check dated 2024-05-22T20:53:01.000Z thumbnail image
  8. Check
    47 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:17:47.000Z thumbnail image

Stay in the know with updates to BMS-986226 Immunotherapy Combo Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BMS-986226 Immunotherapy Combo Clinical Trial page.